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ABSTRACT
We hypothesize that miR-3151, localized to a GWAS-identified chronic 
lymphocytic leukemia (CLL) risk locus (8q22.3), is a tumor suppressor miRNA silenced 
by promoter DNA methylation in CLL. The promoter of miR-3151 was methylated 
in 5/7 (71%) CLL cell lines, 30/98 (31%) diagnostic primary samples, but not 
normal controls. Methylation of miR-3151 correlated inversely with expression. 
Treatment with 5-Aza-2′-deoxycytidine led to promoter demethylation and miR-3151  
re-expression. Luciferase assay confirmed MAP-kinase activating death domain (MADD) 
and phosphoinositide-3-kinase, regulatory subunit 2 (PIK3R2) as direct targets of  
miR-3151. Moreover, restoration of miR-3151 resulted in inhibition of cellular 
proliferation and enhanced apoptosis, repression of MADD and PIK3R2, 
downregulation of MEK/ERK and PI3K/AKT signaling, and repression of MCL1. Lastly, 
miR-3151 methylation was significantly associated with methylation of miR-203 and  
miR-34b/c in primary CLL samples. Therefore, this study showed that miR-3151 is 
a tumor suppressive miRNA frequently hypermethylated and hence silenced in CLL. 
miR-3151 silencing by DNA methylation protected CLL cells from apoptosis through 
over-expression of its direct targets MADD and PIK3R2, hence constitutive activation 
of MEK/ERK and PI3K/AKT signaling respectively, and consequently over-expression 
of MCL1.
INTRODUCTION
B-cell chronic lymphocytic leukemia (CLL), the 
most common blood cancer in the Western countries, 
is characterized by accumulation of neoplastic, small 
B lymphocytes expressing CD5, CD19 and CD23 in 
bone marrow, peripheral blood and other lymphoid 
tissues [1]. CLL cells are protected from apoptosis by 
autocrine proliferation signals and survival stimuli 
from the microenvironment [2, 3]. It is well known that 
B-cell receptor (BCR) signaling is important in CLL 
pathophysiology, resulting in constitutive activation of 
downstream survival pathways including PI3K/AKT, 
MEK/ERK or NF-κB pathways, thereby protecting CLL 
cells from apoptosis, and hence have been exploited as 
targets for molecular therapies [4, 5]. 
DNA methylation refers to the addition of a methyl 
group (–CH3) to the carbon 5 of the cytosine ring, leading 
to the formation of 5-methylcytosine [6]. Many 
human cancers are characterized by a global DNA 
hypomethylation and aberrant, gene-specific DNA 
hypermethylation of tumor suppressor genes (TSGs) [7]. 
To date, numerous TSGs involved in the dysregulation of 
signaling pathways, including SHP1 and SOCS1 regulating 
JAK/STAT signaling, soluble WNT inhibitors 
regulating WNT signaling and CDKN2A and CDKN2B 
regulating the cell-cycle, have been found to be 
hypermethylated in multiple hematological cancers [8–10]. Of 
note, recent studies have identified methylation of additional 
TSGs including DAPK1, ID4 and SFRP1, which are 
implicated in the pathogenesis or prognosis of CLL [11–13].
microRNAs (miRNAs) have been discovered as a 
class of single-stranded, non-protein-coding small RNAs 
of 19 to 25 nucleotides in length. miRNAs regulate 
expression of protein-coding genes by binding to specific 
seed region binding site on 3′ untranslated region (3′UTR) 
Oncotarget44423www.impactjournals.com/oncotarget
of the target mRNAs, leading to translational repression 
or mRNA degradation of the target genes [14]. miRNAs 
involved in CLL may be oncogenic or tumor suppressive. 
Recently, a miRNA signature comprising 18 putative 
oncogenic miRNAs and seven putative tumor suppressor 
miRNAs has been identified in CLL by comparing CLL 
cells with normal B cells [15]. An alternative mechanism 
of miRNA silencing in cancer is DNA methylation of 
promoter-associated CpG island. Indeed, methylation 
silencing of tumor suppressor miRNAs including 
miR-203, miR-124-1, miR-34b/c, and miR-9-3 have 
been demonstrated in CLL, hence implicated in CLL 
leukemogenesis [16–19].
Recently, the updated GWAS meta-analysis, which 
included a total of 3,100 individuals with CLL cases 
and 7,667 controls, identified 12 new CLL susceptibility 
loci, some of which harbor apoptosis-regulating tumor 
suppressor genes (such as BIM, NOXA) downregulated in 
CLL [20]. These finding prompted us to postulate that tumor 
suppressive miRNAs might be present in the neighborhood 
of these susceptibility loci, and their expression 
silenced by DNA hypermethylation. Interestingly, 
bioinformatics analysis showed that miR-3151, 
with a promoter-associated CpG island, is localized to 
intron 1 of the brain and acute leukemia cytoplasmic 
(BAALC) gene at 8q22.3, one of the GWAS-identified 
risk loci. Herein, we studied miR-3151 methylation in a 
representative cohort to define its role in CLL pathogenesis. 
RESULTS
MSP of miR-3151 in normal controls and CLL  
cell lines
As illustrated in the schematic diagram showing 
the promoter region of miR-3151 and its host gene 
BAALC (Supplementary Figure S1A), methylation of the 
promoter of miR-3151 was studied by MSP and bisulfite 
pyrosequencing using primers designed at the CpG island 
upstream to the transcription start site (TSS). None of 
the 9 healthy donor samples (N1 to N9) showed aberrant 
methylation of miR-3151 (Figure 1A). Direct sequencing 
analysis of the miR-3151 M-MSP products from a bisulfite-
treated methylation positive control showed expected 
conversion of unmethylated cytosine to thymidine after 
PCR (but not methylated cytosine), indicating complete 
bisulfite conversion and MSP specificity (Figure 1B). 
Moreover, in CLL cell lines, WAC3CD5+ revealed 
complete methylation, MEC1, 232B4, HG3 and I83-E95 
showed partial methylation, whereas MEC2 and CLL-AAT 
displayed complete unmethylation of miR-3151 (Figure 1C). 
Quantitative bisulfite pyrosequencing validated the MSP 
methylation statuses (MM, MU, UU) of the CLL cell 
lines (Supplementary Figure S2). In addition, the mean 
expression of miR-3151 in methylated CLL cell lines was 
significantly lower than that in unmethylated cell lines, 
and hence a higher ∆Ct (∆Ct miR-3151 – ∆Ct RNU48) 
(P = 0.01) (Figure 1D). 
To examine if the expression of miR-3151 correlated 
to that of its host gene BAALC in CLL, the expression of 
BAALC was studied by qRT-PCR using Taqman assay in 
seven CLL cell lines. Results showed that the expression 
of BAALC in partially methylated cell lines (MEC1, 
232B4, HG3 and I83-E95) was significantly lower than 
that of completely unmethylated CLL cell lines (MEC2 
and CLL-AAT) (P = 0.05) (Supplementary Figure S1B), 
as indicated by a higher ∆Ct (Ct BAALC - Ct GAPDH) 
in partially methylated than completely unmethylated 
CLL cell lines. Therefore, expression of miR-3151 was 
correlated with that of its host gene BAALC in most CLL 
cell lines, except the completely methylated cell line 
(WAC3CD5+ cells).
MSP of miR-3151 in CLL primary samples at 
diagnosis
Methylation of miR-3151 was detected in 30/98 
(31%) of primary samples at diagnosis (Figure 2A). 
Importantly, in 20 samples with both DNA and RNA, 
methylation of miR-3151 (N = 6) was associated with 
lower miR-3151 expression than those without miR-3151 
methylation (N = 14, P = 0.04) (Figure 2B). There was 
no significant correlation between miR-3151 methylation 
and the diagnostic lymphocyte count, hemoglobin level, 
platelet count, age, gender or high-risk karyotypes. 
The median OS of CLL patients with and without 
miR-3151 methylation were 89 and 69 months respectively 
(P = 0.65). Among the 98 samples, concomitant 
methylation study of miR-3151 with miR-203 was 
performed in 50 patients, miR-34b/c in 78 patients, and 
miR-34a in 78 primary CLL samples respectively. The data 
for methylation of each of miR-203, miR-34b/c or miR-34a 
have been published previously [16, 18]. Of these, five 
(10%) patients showed concomitant methylation of 
miR-203 and miR-3151 (P = 0.002), 10 (13%) patients 
concomitant methylation of miR-34b/c and miR-3151 
(P = 0.001), and two (2.6%) patients concomitant 
methylation of miR-34a and miR-3151 (P = 0.07).
5-AzadC treatment of WAC3CD5+ and MEC2 
cells
To test if promoter methylation led to downregulated 
expression of miR-3151, both CLL cell lines completely 
methylated (WAC3CD5+) and completely unmethylated 
(MEC2) for miR-3151 were independently treated with 
a hypomethylating agent. Treatment with 5-AzadC in 
WAC3CD5+ cells led to promoter demethylation as 
evidenced by the emergence of U-MSP signal, and hence, 
with a corresponding increase of miR-3151 and BAALC 
expression on Day 7 (Figure 3A, Supplementary Figure 
S1C and Figure S2C). By contrast, treatment with 5-AzadC 
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in MEC2 cells did not render a change in the methylation 
status and expression of miR-3151 (Figure 3B).
Effect of miR-3151 over-expression in 
WAC3CD5+ cells  
As miR-3151 is frequently methylated and under-
expressed in CLL cell lines and primary samples, we 
postulated that it might act as a tumor suppressive 
miRNA, and hence investigated tumor suppressor function 
of miR-3151 in CLL cells in vitro. By TaqMan stem-loop 
quantitative RT-PCR, over-expression of miR-3151 was 
shown to be induced in WAC3CD5+ cells 48 hours after 
transfection (Figure 4A). Overexpression of miR-3151 led 
to a 20% reduction of cell proliferation as measured by 
MTT assay (P = 0.04, Figure 4B), an addition of 12% dead 
cells by Trypan blue exclusion assay (P = 0.003, Figure 4C) 
and an addition of 10% apoptosis cells as shown by 
Annexin V and PI staining (P = 0.03, Figure 4D), 
suggesting a tumor suppressive role of miR-3151 in CLL. 
Identification of PIK3R2 and MADD as direct 
targets of miR-3151 
To further understand the mechanism by which 
miR-3151 regulates cell proliferation and apoptosis in CLL 
cells, potential direct targets of miR-3151 were screened 
using four computational prediction softwares including 
TargetScan Version 6.2, DIANA-microT v3.0, miRDB and 
miRanda. Two putative targets, MADD and PIK3R2, with 
known oncogenic properties were concomitantly predicted 
by all these four miRNA target prediction algorithms, and 
hence were further studied. 
To confirm MADD and PIK3R2 to be direct targets 
of miR-3151, wild-type and mutant 3′UTR of MADD and 
PIK3R2 luciferase reporter constructs were generated 
(Figure 5A). For each of MADD and PIK3R2, the wild-
type or mutant luciferase construct was co-transfected with 
miR-3151 mimic into HeLa cells for 48 hours. As shown in 
Figure 5B, as compared with co-transfection of scrambled 
oligonucleotides control, a 35% reduction of luciferase 
Figure 1: Methylation of miR-3151 in normal donors and cell lines. (A) M-MSP of miR-3151 showed that the positive control 
(PC) was completely methylated while all 9 normal controls were completely unmethylated. In the U-MSP, the methylated control PC was 
totally unmethylated, but all normal controls are totally methylated. (B) Sequence analysis of the miR-3151 M-MSP product from bisulfite-
treated positive control DNA showed that the cytosine (C) residues of CpG dinucleotides were methylated and remained unchanged, 
whereas all the other C residues were unmethylated and were converted to thymidine [T], suggesting complete bisulfite conversion and 
specificity of MSP. (C) In 7 CLL cell lines, WAC3CD5+ revealed complete methylation, MEC1, 232B4, HG3 and I83-E95 were partially 
methylated, while MEC2 and CLL-AAT were completely unmethylated of miR-3151. (D) Stem-loop quantitative RT-PCR analysis of 
miR-3151 expression in methylated (N = 5) versus unmethylated CLL cell lines (N = 2). ∆Ct, Ct miR-3151-Ct RNU48. RNU48 was used 
as reference of miR-3151 expression by 2−∆∆CT method.
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Figure 2: Methylation of miR-3151 in primary samples. (A) Promoter methylation of miR-3151 in CLL primary samples. 
(B) Quantitative RT-PCR analysis of miR-3151 expression between miR-3151 methylated primary samples (N = 6) and unmethylated 
samples (N = 14). ∆Ct, Ct miR-3151-Ct RNU48. RNU48 was regarded as internal control. Error bars represent standard deviation.
Figure 3: Effect of 5-Aza-2′-deoxycytidine (5-AzadC) treatment on WAC3CD5+ and MEC2 cells. U-/M-MSP of miR-3151 
promoter methylation status and stem-loop quantitative RT-PCR analysis of mature miR-3151 expression in (A) WAC3CD5+ cells and (B) 
MEC2 cells before and after treatment with 0.5 μM 5-AzadC for 7 days. ∆Ct, Ct miR-3151-Ct RNU48. RNU48 was used as reference for 
data analysis of miR-3151 expression by 2−∆∆CT method. 
Oncotarget44426www.impactjournals.com/oncotarget
activity was observed in miR-3151 co-transfected with 
wild-type MADD-3′UTR. This suppression was abolished 
when miR-3151 was co-transfected with Mut MADD-
3′UTR (with 4 point mutations in seed region binding 
site) or Del MADD-3′UTR (with miR-3151 binding site 
deleted). Similarly, as compared with the scrambled 
oligonucleotides control, over-expression of miR-3151 
with wild-type PIK3R2-3′UTR led to a 65% reduction 
of luciferase activity. By contrast, the luciferase activity 
was not suppressed by miR-3151 when 6 point mutations 
were introduced in each of the three miR-3151 binding 
sites on the 3′UTR of PIK3R2 (Mut PIK3R2-3′UTR). 
These findings confirmed that MADD and PIK3R2 are 
both direct targets of miR-3151. Moreover, in CLL 
cell lines, whether methylation and hence silencing of 
miR-3151 correlates with increased expression of MADD 
and PIK3R2 was studied by qRT-PCR. Results showed 
that a trend of methylation was associated with higher 
expression of the target genes, as indicated by the lower ∆Ct 
(Ct MADD/PIK3R2 - Ct GAPDH) in methylated cell lines 
(MM or MU), as compared with those in unmethylated 
cell lines (UU) (Supplementary Figure S3), confirming 
the role of methylation of miR-3151 in the regulation of 
MADD and PIK3R2 in CLL cells.
miR-3151 overexpression suppresses CLL cell 
proliferation by directly targeting MADD and 
PIK3R2 implicated in MEK/ERK and PI3K/
AKT signaling
miRNAs may affect mRNA stability or translation 
of target protein-coding genes [21]. To address the 
biological significance of miR-3151 methylation in CLL 
cells, we evaluated the mRNA and protein expression of 
Figure 4: Over-expression of miR-3151 in CLL cells. WAC3CD5+ cells, completely methylated for miR-3151, were transfected 
with miR-3151 mimic or scrambled oligonucleotides control. Cells were harvested for functional assays 48 hours after transfection. 
(A) Stem-loop quantitative RT-PCR analysis of miR-3151 expression at 48 hours after transfection. ∆Ct, Ct miR-3151-Ct RNU48. RNU48 
was chosen as reference using the 2−∆∆CT method. (B) Relative cell proliferation of CLL cells upon over-expression of miR-3151 was 
measured by MTT assay. Column, mean percentage of cell proliferation from three experiments conducted in triplicate. (C) Percentage of 
dead cells was measured by Trypan blue exclusion assay. Column, mean percentage of cell death from three experiments with triplicate 
in each. (D) The percentage of apoptotic CLL cells after miR-3151 transfection was assessed by flow cytometry using FITC Annexin V-PI 
staining. Left panel: represented average percentage of apoptotic cells from three independent experiments. Right panel: representative 
results. Error bars represent standard deviation.
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its target genes by qRT-PCR and Western blot respectively 
after over-expression of miR-3151 in WAC3CD5+ cells 
with complete miR-3151 methylation. Upon miR-3151 
over-expression, MADD and PIK3R2 mRNA levels were 
significantly downregulated by 34% (P = 0.02) and 28% 
(P = 0.04) respectively (Figure 6A). 
Moreover, at the protein level, restoration of 
miR-3151 in completely methylated cells resulted in 66% 
downregulation of MADD protein, in association with 
77% repression of the downstream phospho-ERK1/2 
protein, indicating that miR-3151 may function as a tumor 
suppressor by inhibiting MADD/MEK/ERK signaling 
(Figure 6B). Furthermore, miR-3151 over-expression also 
led to the 58% downregulation of PIK3R2 protein, which 
was associated with a 75% reduction of the downstream 
phospho-AKT (Thr308) protein but not phospho-AKT 
(Ser473), showing that miR-3151 methylation/silencing 
accounted for constitutive PIK3R2/PI3K/AKT activation 
in CLL (Figure 6B). Finally, MCL1 is an important anti-
apoptotic protein upregulated by ERK or AKT signaling 
in many cancers including CLL. As shown in Figure 6B, 
MCL1 protein expression was repressed by 65% upon 
miR-3151 over-expression, thereby testifying the tumor 
suppressor function of miR-3151 in CLL. The average of 
quantitative densitometry of the relative protein expression 
(including MADD, PIK3R2, P-ERK1/2, P-AKT (Thr308), 
P-AKT (Ser473) and MCL1) from two independent 
experiments were plotted as shown in Figure 6C.
To further confirm the role of PIK3R2 and 
MADD in miR-3151-mediated tumor suppression in 
Figure 5: Identification of direct targets MADD and PIK3R2 for miR-3151. (A) Sequence complementarity of potential 
miR-3151 binding sites in MADD-3′UTR and PIK3R2-3′UTR. 3′UTR of MADD includes one putative miR-3151 binding site while 3′UTR 
of PIK3R2 is composed of three putative miR-3151 binding sites (S1–S3). Corresponding mutant 3′UTR are shown below. The mutated 
nucleotides in the 3′UTR of MADD or PIK3R2 are indicated in red. Dash line, deletion region in 3′UTR. (B) Luciferase constructs 
carrying wild-type or mutant 3′UTR of target gene (MADD or PIK3R2) was co-transfected with miR-3151 as compared with scrambled 
oligonucleotides control in HeLa cells for 48 hours. Mut PIK3R2-3′UTR contained a three mutated sites, namely Mut S1, Mut S2 and Mut 
S3, simultaneously. Del MADD-3′UTR was deleted the binding site sequence (5′-CCCCACA-3′). Firefly luciferase activity was normalized 
to the Renilla lucifrease activity. Column, mean of normalized luciferase activity in triplicates after three independent transfections. Error 
bar represents standard deviation.
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Figure 6: miR-3151 regulates the MEK/ERK and PI3K/AKT signaling by repressing MADD and PIK3R2 respectively. 
(A) MADD and PIK3R2 mRNA expression was downregulated upon miR-3151 transfection in WAC3CD5+ cells as compared to scrambled 
oligonucleotides control. ∆Ct, Ct MADD/PIK3R2-Ct GAPDH. GAPDH was used as reference for data analysis of MADD/PIK3R2 
expression by 2−∆∆CT method. Error bars represent standard deviation. (B) Western analysis showed a decrease of MADD and PIK3R2 
protein by introduction of miR-3151 mimic in WAC3CD5+ cells, followed by the reduced p-ERK1/2, P-AKT (Thr308) and MCL1 protein, 
instead of P-AKT (Ser473). Total levels of ERK1/2 and AKT were not affected. For MADD, PIK3R2 and MCL1, Actin was regarded 
as the endogenous normalizer and densitometric analysis of normalized protein levels are indicated above the western blot. (C) Two 
independent transfection were performed. Columns represent the average of quantitative densitometry of the relative protein expression 
(including MADD, PIK3R2, P-ERK1/2, P-AKT (Thr308), P-AKT (Ser473) and MCL1) from two independent experiments. Error bars 
represent standard deviation.
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CLL cells, knockdown of each of PIK3R2 and MADD 
was performed in WAC3CD5+ cells with complete 
miR-3151 methylation. Upon successful knockdown 
of PIK3R2 as shown by reduced levels of both mRNA 
and protein (Supplementary Figure S4A-B), a 30% 
reduction of cell proliferation by MTT assay (P = 0.04) 
(Supplementary Figure S4C) and a 13% increase of dead 
cells measured by Trypan blue exclusion assay (P < 0.01) 
were demonstrated (Supplementary Figure S4D), as 
compared with control siRNA. Similarly, knockdown 
of MADD in WAC3CD5+ cells (Supplementary Figure 
S5A-B) showed 20% decreased cellular proliferation by 
MTT assay (P = 0.01) (Supplementary Figure S5C) and 
13% increased cell death by Trypan blue exclusion assay 
(P < 0.01) (Supplementary Figure S5D). Collectively, 
these data confirmed that the tumor suppressor function 
of miR-3151 was mediated via downregulation of PIK3R2 
and MADD (Figure 6).
DISCUSSION
A few observations were made in this study.
Firstly, we demonstrated the tumor-specific 
methylation of miR-3151 in CLL as evidenced by frequent 
methylation in CLL cell lines and primary samples but not 
normal controls, including CD19-sorted normal B-cells. 
By contrast, miR-9-2 and miR-373 are methylated in both 
tumor cells and the corresponding normal counterparts, 
indicating a tissue-specific and not tumor-specific 
methylation pattern [17, 22]. 
Secondly, DNA methylation of miR-3151 was 
associated with reversible gene silencing. This was 
supported by, first, an inverse correlation between 
methylation status and expression of miR-3151 in cell 
lines and primary CLL cells. Moreover, hypomethylation 
treatment of WAC3CD5+ cells with 5-AzadC, which was 
completely methylated of miR-3151, led to demethylation 
and re-expression of miR-3151. 
Thirdly, we showed that miR-3151 is a tumor 
suppressor miRNA in CLL, in contrast to recent reports 
that miR-3151 is oncogenic in cytogenetically normal 
acute myeloid leukemia (AML) [23, 24], in which 
miR-3151 functioned as the oncogenic driver targeting 
TP53 [25]. By contrast, herein, miR-3151 is tumor 
suppressive in CLL as evidenced by decreased 
cell proliferation and enhanced apoptosis upon 
over-expression. Similarly, miR-9 has been shown to 
be tumor suppressive in ovarian cancer and CLL via 
inhibition of NF-κB pathway but oncogenic in breast 
cancer via activation of β-catenin signaling [17, 26, 27]. 
Therefore, a miRNA can be oncogenic in one but tumor 
suppressive in another cancer type.
Fourthly, in vitro activation of BCR signaling by 
anti-IgM BCR antibodies induced activation of both 
MEK/ERK and PI3K/AKT signaling in CLL, thereby 
protecting CLL cells from apoptosis [4, 28]. Indeed, 
by luciferase assays, MADD and PIK3R2 have been 
validated as direct novel targets of miR-3151. MADD, 
a splice variant of IG20 (insulinoma-glucagonoma 20) 
overexpressed in cancer cells [29], is crucial for RAS/
MEK/ERK activation by facilitating recruitment of Grb2 
to the receptor-mediated signaling complex [30]. On the 
other hand, PIK3R2 is a subunit of a protein complex 
for activation of PI3K signaling, which comprises p85 
(p85α and p85β [alias PIK3R2]) and a p110 catalytic 
subunit (α, β, γ) [31]. Indeed, the oncogenic role of PIK3R2 
has been demonstrated in breast and colon cancer, in 
which over-expression of PIK3R2 with concomitant AKT 
activation correlated with tumor progression in vivo [32]. 
Herein, over-expression of miR-3151 promoted 
apoptosis of CLL cells via repression of MADD and 
p-ERK1/2, and hence inhibition of MADD/RAS/ERK 
signaling. On the other hand, functional activation of 
AKT is dependent on the phosphorylation of two residues, 
Ser473 in the hydrophobic motif or Thr308 in the 
activation loop [33]. Recently,  Thr308 phosphorylation 
has been found a better biomarker than Ser473 
phosphorylation for AKT activation [34]. Similarly, 
our data showed that the over-expression of miR-3151 
enhanced apoptosis of CLL cells through suppression of 
PI3K/AKT pathway by repressing PIK3R2, which was 
associated with profound downregulation of Thr308 but 
not Ser473 phosphorylation. Therefore, activation of 
PI3K signaling associated with miR-3151-methylation 
in CLL is mediated by Thr308 but not Ser473 
phosphorylation. 
In cancer, both ERK and AKT signaling confer 
resistance to apoptosis via upregulation of a panel of 
anti-apoptotic proteins including MCL1, X-linked 
inhibitor of apoptosis protein (XIAP) and BCL-xL. 
MCL1 has been shown to inhibit apoptosis in CLL 
[35–37]. Indeed, restoration of miR-3151 mimic in CLL 
cells resulted in repression of MCL1 protein. Taken 
together, our data suggested that miR-3151 methylation 
led to constitutive ERK and AKT activation, and hence 
over-expression of MCL1, thereby protecting CLL cells 
from apoptosis. 
Last but not least, methylation of miR-3151 
(chr. 8q22.3) was associated with that of miR-203 
(chr 14q32) and miR-34b/c (chr 11q23), which are 
localized to different chromosomal regions. miR-34b/c and 
miR-203 have also been shown to target CREB 
independently, and hence methylation of these miRNAs 
may render upregulation of multiple oncogenes including 
BCL2 and NF-κB1 [38, 39]. Therefore, these four 
tumor suppressor miRNAs undergoing methylation may 
collaborate to confer proliferation advantages to CLL cells.
In conclusion, our results showed that miR-3151 
was a tumor suppressor miRNA frequently methylated 
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and hence silenced in CLL. Methylation of miR-3151 
in CLL cells conferred resistance to apoptosis through 
over-expression of its direct targets MADD and PIK3R2, 
and hence constitutive activation of RAS/MEK/ERK and 
PI3K/AKT, and consequently over-expression of MCL1 
(Figure 7). 
Figure 7: Model of miR-3151 function in CLL cells. Over-expression of miR-3151 represses PIK3R2 and MADD, which further 
downregulate the PI3K/AKT and MEK/ERK signaling respectively. Thus, miR-3151 methylation protected CLL cells from apoptosis 
through over-expression of direct targets PIK3R2 and MADD, leading to constitutive activation of PI3K/AKT and MEK/ERK signaling 
respectively, with consequent upregulation of MCL1.
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MATERIALS AND METHODS
Patient samples 
Bone marrow samples were collected from 98 
Chinese CLL patients diagnosed according to the 
standard morphologic and immunophenotyping criteria 
as previously [17, 40]. Patient demographics were listed 
in Table 1. The median overall survival (OS) of this 
cohort was 89 months. The median OS of those with 
advanced Rai stage and limited Rai stage were 57 and 
111 months respectively (P = 0.006). Moreover, the 
median OS for those with or without high/intermediate-
risk karyotype were 43 months and 111 months 
respectively (P = 0.04). Of these, the miR-203 (N = 50), 
miR-34b/c (N = 78) and miR-34a (N = 78) methylation 
results have been reported previously [16, 18]. This 
study was approved by the Institutional Review Board 
of Queen Mary Hospital and samples were collected 
with written informed consent and in accordance with 
the Declaration of Helsinki.
Cell lines and culture 
The human CLL cell lines MEC1 and CLL-
AAT were purchased from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen Deutsche GmbH 
(DSMZ) (Braunschweig, Germany) and American Type 
Culture Collection (ATCC) (Manassas, USA) respectively. 
MEC2 [41], I83-E95 [42] and WAC3CD5+ [42] were kind 
gifts from Dr John C. Byrd, Department of Medicine, 
Ohio State University. HG3 and 232B4 were previously 
established by Prof. Anders Rosén, Department of 
Clinical & Experimental Medicine, Linköping University 
[43, 44]. Cell lines were cultured in 90% RPMI 
1640 + 10% FBS, supplemented with 50 U/ml penicillin and 
50 µg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) 
in a humidified atmosphere of 5% CO2 at 37
oC.
Methylation-specific polymerase chain reaction 
(MSP)
DNA was extracted from 98 primary samples, 7 cell 
lines and 9 normal controls (peripheral blood buffy coats 
from healthy donors, N = 3; CD19 sorted peripheral blood 
B cells from healthy donors, N = 3; and bone marrow 
buffy coats from healthy donors, N = 3) using the QIAamp 
DNA Blood Mini Kit (QIAGEN, Germany) and then were 
treated with bisulfite to convert unmethylated cytosine to 
uracil (but unaffecting methylated cytosine) by the EpiTect 
Bisulfite Kit kit (QIAGEN, Hilden, Germany). For each 
bisulfite-treated sample, two sets of primers were used to 
amplify the methylated DNA (methylated-MSP, M-MSP) 
and unmethylated DNA (unmethylated-MSP, U-MSP) 
respectively. Primers and conditions for M-MSP and 
U-MSP of miR-3151 were listed in Table 2. 
Quantitative bisulfite pyrosequencing 
Primers for pyrosequencing were used for the 
amplification of miR-3151 promoter region, which was 
overlapped with the amplicon of MSP. Primers were 
designed by PSQ Assay Design software (Biotage). 
Bisulfite-treated DNA was amplified by PCR with a forward 
primer (5′-ATGGATAGATGGGTTAGAGATTG-3′) 
and a biotinylated reverse primer 
(5′-AATAAACCAAATAAATTCTATCTCC-3′) 
in the following condition: 2 mM/59°C/50X. A 
stretch of DNA with 6 adjacent CpG dinucleotides 
was pyrosequenced using sequencing primer: 
5′- GAGAGTTTAGGGAGTTTTAGTTTT-3′. Bisulfite-
treated DNA (2µl) was used as template in a PCR reaction 
with final volume of 50µl. The PCR products were purified 
and loaded onto 6% non-denaturing polyacrylamide gels 
with a mass ladder (Fermentas) and stained with ethidium 
bromide staining for sizing and quantification. Biotin-
labeled PCR fragments (5 pmoles) of each sample were 
subjected to pyrosequencing using the PSQ96MA System 
(Biotage) and analyzed using PyroQ-CpG 1.0.9, according 
to manufacturer’s instructions.
5-Aza-2′-deoxycytidine (5-AzadC) treatment
Each of WAC3CD5+ and MEC2 cells at 
log-phase was cultured in six-well plates at a density of 
106 cells/ml, with 0.5 µM of 5-AzadC (Sigma-Aldrich, 
St. Louis, MO, USA) for 7 days. Fresh 5-AzadC was 
replaced every 24 hours. Cells of 5-AzadC treatment on 
day 0 and day 7 were harvested.
Quantification of miR-3151, BAALC, MADD and 
PIK3R2
Total RNA was extracted by the mirVana miRNA 
Isolation Kit (Ambion, Austin, TX, USA). miR-3151 
was quantified by the TaqMan MicroRNA RT Kit 
and TaqMan MicroRNA Assay Kit (ABI, Foster City, 
CA, USA) with RNU48 as reference. BAALC was 
quantified by BAALC Taqman Gene Expression Assay 
(Cat. 4351372) (ABI, Foster City, CA, USA), according to 
the manufacturer’s instructions. For MADD and PIK3R2, 
total RNA was reverse transcribed by the QuantiTect 
Reverse Transcription Kit (QIAGEN, Valencia, CA), 
and quantified using SYBR Green Master Mix (ABI, 
Foster City, CA, USA), following the manufacturer’s 
instructions. GAPDH was used as endogenous control 
for data analysis of BAALC, MADD and PIK3R2 [45]. 
The 2−∆∆CT method was used to detect the expression of 
miR-3151 and target genes (MADD and PIK3R2) before 
and after over-expression of miR-3151 in WAC3CD5+ 
cells; and the expression of miR-3151 before and after 
5-AzadC treatment [45]. For comparing the miR-3151 
and target genes (MADD and PIK3R2) expression between 
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methylated and unmethylated CLL cell lines or primary 
samples, ∆CT method is used. Primers for detecting 
the mRNA expression of MADD and PIK3R2 were 
summarized in Supplementary Table S1.
Transfection of miR-3151 
Either precursor miR-3151 mimic (final concentration 
100 nM) (Ambion, Austin, TX, USA) or scrambled 
oligonucleotides control (negative control) was transfected 
into 1 × 106 WAC3CD5+ cells at log phase using 
X-tremeGENE siRNA Transfection Reagent (Roche, Basel, 
Switzerland), according to the manufacturers’ instructions.
Silencing of PIK3R2 and MADD by RNA 
interference
RNA interference by small interfering RNA (siRNA) 
was used to knockdown the expression of PIK3R2 and 
MADD in WAC3CD5+ cells. For knockdown of PIK3R2, 
cells were plated at a density of 1 × 106/ml in a six-
well plate and transfected with 120 nM PIK3R2 siRNA 
(top strand: 5′-GCGGGAACAAUAAGCUGAUTT-3′) or 
control siRNA (GenePharma Biotechnology, Shanghai, 
China) using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s instructions. Cells were cultured and 
analyzed at 72 hours after transfection. For knockdown of 
MADD, cells were transfected with 100nM MADD siRNA 
(Santa Cruz Biotechnology, sc-75726) or control siRNA-A 
(Santa Cruz Biotechnology, sc-37007) and analyzed at 
48 hours after transfection. The efficiency of siRNA was 
determined by qRT-PCR and Western blot.
Cell proliferation and viability assays
MTT assay was used to determine the cellular 
proliferation by colorimetric quantification of purple 
formazan formed from the reduction of yellow 
tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide) by proliferative viable 
cells [46]. Cells were seeded in a 96-well microtitre plate 
at 2× 105 cells/well in 100 µl of medium. Forty-eight 
hours after transfection, each well was added 10 µl of 
5 mg/ml MTT reagent (Sigma-Aldrich) and incubated 
Table 1: The CLL patients demographics (N = 98)
Characteristic Value
Gender (M/F) 67 (68.4%)/31 (31.6%)
Median age (range)—yr 67 (37–91) 
Rai stage (≤ II/> II)* 56 (62.2%)/34 (37.8%)
Median lymphocyte count (range) 16 × 109/L (10–540 × 109/L)
High-risk cytogenetics‡
del (17p) 3 (4.8%)
del (11q) 2 (3.2%)
trisomy 12 11 (17.5%)
Low-risk cytogenetics‡
del (13) 19 (30.2%)
normal karyotype 21 (33.3%)
other karyotype abnormalities 7 (11.0%)
*from 90 patients with clinical data; ‡from 63 patients with cytogenetic data.
Table 2: miR-3151 MSP Primer sequences and condition
miR-3151 Forward primer (5′ to 3′) Reverse primer (5′ to 3′) Tm/cycles/MgCl2
U-MSP GTTTTTGTTTTTGGGTTGTTAT AAAACTCCTACAATACCCA 56°C /35 × /2 mM
M-MSP GTTTTTGTTTTCGGGTCGTTAC CGAAACTCCTACGATACCCG 55°C/ 35 × /1.5 mM
Abbreviations: M-MSP, MSP for the methylated allele; U-MSP, MSP for the unmethylated allele; Tm, annealing 
temperature.
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for 5 hours, followed by adding 100 µl dimethyl sulfoxide 
(DMSO). Then the absorbance at 550 nm with reference 
to 650 nm was measured. Cell viability was analyzed by 
Trypan blue dye exclusion assay under microscope and 
five random microscopic fields were counted for each 
sample. Dead cells (%) = (total number of dead cells per 
microscopic field / total number of cells per microscopic 
field) × 100. MTT assay and Trypan blue dye exclusion 
assay were performed in triplicate in each of the three 
independent transfections.
Cell apoptosis assay
Cellular apoptosis was verified by flow cytometry 
using FITC Annexin V Apoptosis Detection Kit I 
(BD-Pharmingen) as described before [17, 47]. The 
presence of cells with FITC Annexin V positive, 
propidium iodide (PI) negative (early apoptosis) or FITC 
Annexin V positive, PI positive cells (late apoptosis) 
suggests apoptosis. FACS analyses were performed by a 
flow cytometer (FACSCanto II) equipped with FACSDiva 
V6.1.2 software (BD Biosciences). Data were derived 
from three independent transfections.
Plasmid constructs
The full-length 3′UTR of MADD includes one 
putative miR-3151 binding site (819-826 bp of 3′UTR) 
while the 3′UTR of PIK3R2 includes three putative 
miR-3151 binding sites (Site 1, 515–522 bp; Site 2, 
573–579 bp; Site 3, 1170-1176 bp of 3′UTR). The 
3′UTR segments of MADD (~220 bp) and PIK3R2 
(~750 bp) containing putative miR-3151 binding sites 
were respectively amplified and cloned into the NheI and 
SalI sites of a dual firefly/renilla luciferase reporter vector, 
pmirGLO (Promega, Madison, WI, USA). Two different 
types of MADD-3′UTR mutants were constructed using 
the QuikChange Lightning Site-Directed Mutagenesis 
Kit (Stratagene, La Jolla, CA, USA), one with 4 point 
mutations introduced in the seed region binding site 
(Mut MADD-3′UTR) while the other with the entire 
seed region binding site (5′-CCCCACA-3′) deleted 
(Del MADD-3′UTR). For PIK3R2-3′UTR mutant (Mut 
PIK3R2-3′UTR), six point mutations were introduced 
to each of the three binding sites by mutagenesis using 
QuikChange Lightning Multi Site-Directed Mutagenesis 
Kit (Stratagene, La Jolla, CA, USA). The primers for wild-
type and mutant MADD/PIK3R2-3′UTR constructs above 
were summarized in Supplementary Table S1. Wild-type 
and mutant inserts were confirmed by sequencing shown 
in Supplementary Figure S6.
Luciferase reporter assay
Luciferase reporter vector pmirGLO (Wild-type or 
mutant MADD/PIK3R2-3′UTR, 1 µg) was co-transfected 
with either precursor miR-3151 mimic (final concentration 
50 nM) or scrambled oligonucleotides control (final 
concentration 50 nM) into HeLa cells (kind gift from Dr 
Zou, Department of Medicine, The University of Hong 
Kong) using Lipofectamine 2000 (Invitrogen). After 
48 hours transfection, the luminescent signal was 
generated and analyzed by Dual-Luciferase Reporter 
Assay System (Promega), according to the manufacturers’ 
instructions [39]. Firefly luciferase activity was normalized 
to the Renilla luciferase activity. Data represents the 
mean normalized luciferase activity derived from three 
independent transfections with triplicate in each.
Western Blotting 
Western Blots were performed with 20 μg 
protein from each sample. After 48 hours transfection, 
WAC3CD5+ cells were harvested and lysed in RIPA 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.2% 
SDS, 1% Triton X-100, 2 mM EDTA). Protein lysates 
were separated on 10% SDS-PAGE and blotted onto a 
0.2 μm nitrocellulose membrane (Bio-Rad, Hercules, 
CA). The primary antibodies used were for anti-
MADD (1:2000; Abcam), -PIK3R2 (1:1000; Abcam), 
-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) 
(1:1000; Cell Signaling), -p44/42 MAPK (ERK1/2) 
(1:1000; Cell Signaling), -phospho-Akt (Thr308) (1:2000; 
Cell Signaling), -phospho-AKT (Ser473) (1:2000; 
Cell Signaling), -AKT (1:1000; Cell Signaling) and 
anti-actin (1:5000; Sigma-Aldrich, USA) at 4°C overnight. 
Then membranes were washed and incubated with 
anti-rabbit or anti-mouse horseradish peroxidase conjugate 
secondary antibody at room temperature for 1 hour. ECL 
plus Western blotting detection reagent was used for the 
detection of protein signals with X-ray film (Amersham 
Biosciences, Buckinghamshire, UK). Protein bands were 
quantified using densitometry as measured by Quantity 
One 4.6.2 software (Bio-Rad); hence relative protein 
expression was expressed in comparison to corresponding 
control.
Statistical analysis  
In 98 primary CLL samples, the correlation between 
miR-3151 methylation with continuous (mean age, mean 
lymphocyte counts, diagnostic hemoglobin or platelet 
counts) and categorical variables (gender, Rai stage or 
high-risk karyotypes) were analyzed by student’s t-test 
and chi-square test (or Fisher’s exact test) respectively. 
OS is measured from the date of diagnosis to the date 
of last follow-up or death. Survival was plotted by the 
Kaplan–Meier method and compared by the log-rank 
test. OS of CLL patients with limited Rai stage (stage 
0/I/II) was compared with those with advanced Rai 
stage (stage III/IV). Moreover, OS of CLL patients with 
high-risk karyotypes [del(17p), del(11q) or trisomy 12] 
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was compared to those with standard-risk karyotypes 
[del(13q), normal karyotype or other karyotypic changes]. 
Association between methylation of miR-3151 and 
miR-203, -34b/c or 34a was studied by Chi-square test. 
The mean values of MTT assay, Trypan blue exclusion 
assay and cell apoptosis assay in WAC3CD5+ cells 
transfected with precursor miR-3151 mimic (MADD or 
PIK3R2 siRNA) were compared with negative control 
transfected with a scrambled oligo (control siRNA) by 
Student’s t-test. All P values were two-sided. 
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